Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 in High-Risk MDS and AML
NCT01804101Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- May 2013
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cytarabine in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by Fred Hutchinson Cancer Center. Started May 2013; status: completed.
02
Drugs
cytarabine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01804101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01804101.